Amgen Seeks To Leave ESA Woes Behind In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Aranesp sales are stabilizing, and Amgen expects to enter the new year with “steady-state” ESA sales, management says.
You may also be interested in...
G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.
G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement